148 related articles for article (PubMed ID: 36989489)
1. STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.
Tremblay CS; Saw J; Boyle JA; Haigh K; Litalien V; McCalmont H; Evans K; Lock RB; Jane SM; Haigh JJ; Curtis DJ
Blood; 2023 Jul; 142(3):274-289. PubMed ID: 36989489
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
[TBL] [Abstract][Full Text] [Related]
3. A new hope for early T cell precursor acute lymphoblastic leukemia therapy based on STAT5+ leukemic stem cell targeting.
Pelayo R
J Leukoc Biol; 2023 Oct; 114(5):381-383. PubMed ID: 37607260
[TBL] [Abstract][Full Text] [Related]
4. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.
Ribeiro D; Melão A; van Boxtel R; Santos CI; Silva A; Silva MC; Cardoso BA; Coffer PJ; Barata JT
Blood Adv; 2018 Sep; 2(17):2199-2213. PubMed ID: 30185437
[TBL] [Abstract][Full Text] [Related]
5. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.
Nakayama J; Yamamoto M; Hayashi K; Satoh H; Bundo K; Kubo M; Goitsuka R; Farrar MA; Kitamura D
Blood; 2009 Feb; 113(7):1483-92. PubMed ID: 19047679
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
[TBL] [Abstract][Full Text] [Related]
7. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
[TBL] [Abstract][Full Text] [Related]
8. Targeting STAT5B in T-cell acute lymphoblastic leukemia.
Veloso A; Cools J
Blood; 2023 Jul; 142(3):215-217. PubMed ID: 37471110
[No Abstract] [Full Text] [Related]
9. Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.
Suske T; Sorger H; Manhart G; Ruge F; Prutsch N; Zimmerman MW; Eder T; Abdallah DI; Maurer B; Wagner C; Schönefeldt S; Spirk K; Pichler A; Pemovska T; Schweicker C; Pölöske D; Hubanic E; Jungherz D; Müller TA; Aung MMK; Orlova A; Pham HTT; Zimmel K; Krausgruber T; Bock C; Müller M; Dahlhoff M; Boersma A; Rülicke T; Fleck R; de Araujo ED; Gunning PT; Aittokallio T; Mustjoki S; Sanda T; Hartmann S; Grebien F; Hoermann G; Haferlach T; Staber PB; Neubauer HA; Look AT; Herling M; Moriggl R
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618957
[TBL] [Abstract][Full Text] [Related]
10. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.
Neumann M; Coskun E; Fransecky L; Mochmann LH; Bartram I; Sartangi NF; Heesch S; Gökbuget N; Schwartz S; Brandts C; Schlee C; Haas R; Dührsen U; Griesshammer M; Döhner H; Ehninger G; Burmeister T; Blau O; Thiel E; Hoelzer D; Hofmann WK; Baldus CD
PLoS One; 2013; 8(1):e53190. PubMed ID: 23359050
[TBL] [Abstract][Full Text] [Related]
11. MEK1/2 induces STAT5-mediated germline transcription of the TCRgamma locus in response to IL-7R signaling.
Maki K; Ikuta K
J Immunol; 2008 Jul; 181(1):494-502. PubMed ID: 18566415
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential.
Treanor LM; Zhou S; Janke L; Churchman ML; Ma Z; Lu T; Chen SC; Mullighan CG; Sorrentino BP
J Exp Med; 2014 Apr; 211(4):701-13. PubMed ID: 24687960
[TBL] [Abstract][Full Text] [Related]
13. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
14. Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia.
Heltemes-Harris LM; Larson JD; Starr TK; Hubbard GK; Sarver AL; Largaespada DA; Farrar MA
Oncogene; 2016 Jun; 35(26):3454-64. PubMed ID: 26500062
[TBL] [Abstract][Full Text] [Related]
15. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update.
Oliveira ML; Akkapeddi P; Ribeiro D; Melão A; Barata JT
Adv Biol Regul; 2019 Jan; 71():88-96. PubMed ID: 30249539
[TBL] [Abstract][Full Text] [Related]
16. A Stat5b transgene is capable of inducing CD8+ lymphoblastic lymphoma in the absence of normal TCR/MHC signaling.
Bessette K; Lang ML; Fava RA; Grundy M; Heinen J; Horne L; Spolski R; Al-Shami A; Morse HC; Leonard WJ; Kelly JA
Blood; 2008 Jan; 111(1):344-50. PubMed ID: 17890450
[TBL] [Abstract][Full Text] [Related]
17. Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia.
Danis E; Yamauchi T; Echanique K; Zhang X; Haladyna JN; Riedel SS; Zhu N; Xie H; Orkin SH; Armstrong SA; Bernt KM; Neff T
Cell Rep; 2016 Mar; 14(8):1953-65. PubMed ID: 26904942
[TBL] [Abstract][Full Text] [Related]
18. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia.
Ribeiro D; Melão A; Barata JT
Adv Biol Regul; 2013 May; 53(2):211-22. PubMed ID: 23234870
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional activation of mouse TCR Jgamma4 germline promoter by STAT5.
Masui N; Tani-ichi S; Maki K; Ikuta K
Mol Immunol; 2008 Feb; 45(3):849-55. PubMed ID: 17664008
[TBL] [Abstract][Full Text] [Related]
20. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
